Norwood, MA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative ...
(RTTNews) - Corbus Pharmaceuticals Holdings Inc. (CRBP), a clinical-stage drug development company, announced Tuesday that its 52-week Phase 3 RESOLVE-1 study of lenabasum in patients with diffuse ...
Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...
Mycophenolate mofetil (MMF, CellCept) was effective in halting rapidly progressive diffuse cutaneous systemic sclerosis (SSc), but a substantial percentage of patients experienced recurrences when the ...
SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...
Please provide your email address to receive an email when new articles are posted on . Although lenabasum failed to meet its efficacy endpoint in a trial of patients with diffuse cutaneous systemic ...
Age, specific disease-related elements, and treatment with glucocorticoids independently affect the risk for osteoporosis among patients with systemic sclerosis. Age, specific disease-related elements ...
Despite a lack of definitive evidence supporting their efficacy, nonselective immunosuppressive drugs are frequently prescribed for patients with systemic sclerosis (SSc). An analysis of data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback